Dyne Therapeutics, Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 39/100
What the filing says
Dyne Therapeutics priced 18.3 million shares at $20.50 per share on July 21, 2026, generating gross proceeds of $375.15 million; underwriters granted 30-day option for 2.745 million additional shares at same price. Morgan Stanley and Jefferies are lead underwriters. Deal expected to close July 23, 2026, subject to customary conditions.
Why this rating
Material capital raise (~40% of company market cap) provides meaningful cash, but secondary offering dilutes existing shareholders. Neutral pricing relative to market; ordinary financing event.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.